Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Amarin Corporation plc (AMRN)

NCM · Drug Manufacturers - General

$13.95+0.13 (+0.94%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$292.5M
P/E (TTM)
EPS
$-1.61
Div Yield
52W Range
$12.96–$20.90
Beta
0.80

Company overview

Next earnings: 2026-07-29(1d)

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Peers in Drug Manufacturers - General

All in industry →

Recent press releases

April 2026

3 months agoDEF 14AHealthcare

AMARIN CORP PLC\UK — DEF 14A Filing

AMRNAMARIN CORP PLC\UK

# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)**. Think of it as an invitation and information packet for Amarin's shareholders. It's sent ahead of the **Annual General Meeting (AGM)** scheduled for **May 13, 2026**, to explain what will be voted on and provide key comp

Read summaryView on SEC EDGAR

March 2026

4 months agoPRE 14AHealthcare

AMARIN CORP PLC\UK — PRE 14A Filing

AMRNAMARIN CORP PLC\UK

# 🧾 What This Document Is This is a **PRELIMINARY proxy statement** (form PRE 14A) for **Amarin Corporation plc**. It's a formal notice and information packet sent to shareholders ahead of the company's **2026 Annual General Meeting**. Think of it as the agenda and instruction manual for a company'

Read summaryView on SEC EDGAR

SEC filings

All filings →
2 recent filings shown in the timeline above. View all SEC filings →

Amarin Corporation plc has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30

People at Amarin Corporation plc

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$41.0M
NI -$15.7M
06/25
$46.6M
NI -$14.1M
09/25
$49.7M
NI -$7.7M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.02
Prior: $-0.03
Revenue sparkline